CAPITAL Chemist Southlands and veteran-owned medicinal cannabis company Provocatus have tried to close an unmet need for veterans suffering from chronic pain.
Capital Chemist Group Business Manager Andrew Topp (pictured left) said the pharmacy group is committed to helping veterans access the most appropriate medications to help manage their conditions.
In 2022 Provocatus launched an Australian-first compassionate access program called the Veteran Access Scheme (VAS) for those who faced a health equity issue when they sought treatment with medicinal cannabis.
"Our veterans face extended delays in accessing medicinal cannabis treatment due to processing times through the Department of Veteran Affairs," said Capital Chemist Group Business Manager Andrew Topp.
"Capital Chemist Southlands has extensive experience in dispensing medicinal cannabis and our relationship with Provocatus is another means to provide support to a vulnerable community," Topp said.
Provocatus Managing Director Kasey Mumford added, "the VAS provides veterans with a bridge to access treatment while waiting for their DVA funding approval".
"Many of our staff are veterans and, from their own life experiences, understand the trauma that many of our patients are dealing with."
To date, the VAS has assisted more than 300 veterans access treatment and has raised more than $250,000 to subsidise their treatment, said Mumford.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Jun 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Jun 23
